Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

NCT04191187 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT04191187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04191187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 2
Overall status
Completed
Start date
December 6, 2019
Completion date
February 14, 2024
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, biphenotypic acute leukemia, burkitt lymphoma, chronic myelogenous leukemia, hodgkin lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, myelodysplastic syndromes, myeloproliferative neoplasm, prolymphocytic leukemia, relapsed chronic lymphocytic leukemia, relapsed follicular lymphoma, relapsed large cell lymphoma, relapsed marginal b-cell lymphoma, relapsed small lymphocytic lymphoma, relapsed t-cell lymphoma, undifferentiated leukemia